Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an exclusive global license for opevesostat (MK-5684/ODM-208) and other CYP11A1 targeting candidates, following a mutual agreement with Orion Corporation. This pivotal deal marks a significant advancement in the treatment of prostate […]
Ami Organics Limited, a global leader in manufacturing advanced pharmaceutical intermediates and specialty chemicals, has signed a definitive agreement with Fermion, a subsidiary of Orion Corporation, Finland. This agreement marks the addition of two more advanced pharmaceutical intermediates to the company’s manufacturing portfolio for Fermion. The intermediates, to be produced under this agreement, will be […]
Ami Organics has signed a multi-year, multi-tonne agreement with Fermion, a wholly-owned subsidiary of Finland-based Orion Corporation for the supply of an intermediate for its patented product. Based in India, Ami Organics is involved in manufacturing advance pharmaceutical intermediates and speciality chemicals. The company is claimed to have developed and commercialized more than 450 pharma […]
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that target cytochrome P450 11A1 (CYP11A1). ODM-208, which is an oral, non-steroidal inhibitor of CYP11A1, is presently being assessed by the Finnish pharma company in a phase 2 clinical trial for […]